FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 33

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

625

HTML

4474

Figures (1-2)

208

Tables (1-4)

235

Sum=5542

Sep 7, 2012 (publication date) through Nov 26, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Sep 7, 2012; 18(33): 4533-4541
Published online Sep 7, 2012. doi: 10.3748/wjg.v18.i33.4533

Table 1 Characteristics of the 63 patients with metastatic pancreatic cancer treated with FOLFIRI after failure of gemcitabine and platinum-salts

Characteristics	Data
Age (yr)
Median	59 (range: 24-81)
Sex (%)
Male	33 (52.4)
Performans status (%)
PS 0	27 (42.9)
PS 1	24 (38.1)
PS 2	12 (19.0)
Liver metastases (%)
Present	51 (81.0)
Number of previous lines before FOLFIRI (%)
1	19 (30.2)
2	39 (61.9)
≥ 3	5 (7.9)

Citation: Neuzillet C, Hentic O, Rousseau B, Rebours V, Bengrine-Lefèvre L, Bonnetain F, Lévy P, Raymond E, Ruszniewski P, Louvet C, Hammel P. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. World J Gastroenterol 2012; 18(33): 4533-4541
URL: https://www.wjgnet.com/1007-9327/full/v18/i33/4533.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i33.4533